ClearPoint Neuro Inc vs Eli Lilly And Co — how do they compare? ClearPoint Neuro Inc trades at $14.86 (market cap $454.21M), while Eli Lilly And Co trades at $1,213.85 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 2377.8× ClearPoint Neuro Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | LLY | |
|---|---|---|
Market Cap | $454.21M | $1.08T |
Sector | Health | Health |
52-Week High | $29.60 | $1.24K |
52-Week Low | $8.66 | $639.43 |
Enterprise Value | $488.79M | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.
The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →